Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia

To elucidate the degree of genetic polymorphisms CYP2C19 (CYP2C19*2, CYP2C19*3) of key drug metabolizing enzymes on the antiplatelet effect of clopidogrel response in patients with acute ischemic stroke from Saudi Arabia. A case-control study carried out at Neurology Clinics at Asser Central Hospita...

Full description

Saved in:
Bibliographic Details
Published in:Neurosciences (Riyadh, Saudi Arabia) Saudi Arabia), 2017-01, Vol.22 (1), p.31-37
Main Authors: Alhazzani, Adel A, Munisamy, Murali, Karunakaran, Gauthaman
Format: Article
Language:English
Subjects:
Case-Control Studies
Clopidogrel
Clopidogrel - pharmacology
Clopidogrel - therapeutic use
Cytochrome P-450 CYP2C19 - genetics
Dosage and administration
Drug Resistance - genetics
Drug therapy
Female
Gene Frequency
Genetic aspects
Genetic polymorphisms
Humans
Male
Middle Aged
Original
Platelet Aggregation - drug effects
Polymorphism, Genetic - genetics
Risk factors
Saudi Arabia
Stroke
Stroke - drug therapy
Stroke - genetics
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To elucidate the degree of genetic polymorphisms CYP2C19 (CYP2C19*2, CYP2C19*3) of key drug metabolizing enzymes on the antiplatelet effect of clopidogrel response in patients with acute ischemic stroke from Saudi Arabia. A case-control study carried out at Neurology Clinics at Asser Central Hospital, Abha, Kingdom of Saudi Arabia from October 2015 to January 2016 and included 25 stroke patients responding to clopidogrel therapy and 25 stroke patients non responding to clopidogrel monotherapy. After obtaining their informed consent, the blood samples were collected and genotyped for CYP2C19 polymorphisms by the polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP Method). Allele frequencies were derived from genotypic data and platelet aggregation was measured using multiple electrode aggregometry on the multiplate analyser. Chi Square tests, p-values, odds ratio (OR) and corresponding confidence intervals were calculated for each polymorphism. The CYP2C19*2 (681G>A) and CYP2C19*3 (636 G>A) polymorphism were seen to be in Hardy-Weinberg equilibrium and showed significant allelic and genotypic association between responders and non-responders to clopidogrel (p
ISSN:1319-6138
DOI:10.17712/nsj.2017.1.20160303